相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Availability, prices, and affordability of selected essential cancer medicines in a middle-income country - the case of Mexico
Daniela Moye-Holz et al.
BMC HEALTH SERVICES RESEARCH (2020)
Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead
Anna Kaltenboeck
VALUE IN HEALTH (2020)
Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis
Kerstin N Vokinger et al.
LANCET ONCOLOGY (2020)
Effectiveness of National Pricing Policies for Patent-Protected Pharmaceuticals in the OECD: A Systematic Literature Review
Dominik J. Wettstein et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2019)
The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico
Daniela Moye-Holz et al.
VALUE IN HEALTH REGIONAL ISSUES (2019)
Availability of anticancer medicines in public and private sectors, and their affordability by low, middle and high-income class patients in Pakistan
Muhammad Rehan Sarwar et al.
BMC CANCER (2018)
Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden
Alessandra Ferrario
VALUE IN HEALTH (2018)
Access to innovative cancer medicines in a middle-income country - the case of Mexico
Daniela Moye-Holz et al.
JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE (2018)
RARE CANCERS, NO RARE SOLUTIONS: RISK SHARING ARRANGEMNTS TO REIMBURSE MEDICINES FOR RARE CANCERS IN AUSTRALIA
H. Tuffaha et al.
VALUE IN HEALTH (2018)
Effects of prescription restrictive interventions on antibiotic procurement in primary care settings: a controlled interrupted time series study in China
Yuqing Tang et al.
COST EFFECTIVENESS AND RESOURCE ALLOCATION (2018)
Essential medicines for universal health coverage
Veronika J. Wirtz et al.
LANCET (2017)
The high price of anticancer drugs: origins, implications, barriers, solutions
Vinay Prasad et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases
Margaret Ewen et al.
PLOS ONE (2017)
IMPACT OF TIME TO REIMBURSEMENT OF DRUG TREATMENTS FOR NON-SMALL CELL LUNG ON PATIENT OUTCOMES IN EUROPE AND LATIN AMERICA
N. Smith et al.
VALUE IN HEALTH (2017)
Policy approaches to improve availability and affordability of medicines in Mexico - an example of a middle income country
Daniela Moye-Holz et al.
GLOBALIZATION AND HEALTH (2017)
A global comparison of the cost of patented cancer drugs in relation to global differences in wealth
Daniel A. Goldstein et al.
ONCOTARGET (2017)
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review
Pawel Kawalec et al.
FRONTIERS IN PHARMACOLOGY (2017)
Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future
Kim Pauwels et al.
FRONTIERS IN PHARMACOLOGY (2017)
How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries
Sabine Vogler et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2017)
Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region
Shahrzad Salmasi et al.
BMC CANCER (2017)
Country and regional variations in purchase prices for essential cancer medications
Raphael E. Cuomo et al.
BMC CANCER (2017)
Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund
A. Aggarwal et al.
ANNALS OF ONCOLOGY (2017)
Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data
Rasha Khatib et al.
LANCET (2016)
Price, value, and the cost of cancer drugs
Tito Fojo et al.
LANCET ONCOLOGY (2016)
Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study
Sabine Vogler et al.
LANCET ONCOLOGY (2016)
Actual costs of cancer drugs in 15 European countries
Wim H. van Harten et al.
LANCET ONCOLOGY (2016)
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis
Swathi Iyengar et al.
PLOS MEDICINE (2016)
Progress and remaining challenges for cancer control in Latin America and the Caribbean
Kathrin Strasser-Weippl et al.
LANCET ONCOLOGY (2015)
Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden
Alessandra Ferrario et al.
SOCIAL SCIENCE & MEDICINE (2015)
Commentary: Making middle income countries pay full price for drugs is a big mistake
Priti Radhakrishnan
BMJ-BRITISH MEDICAL JOURNAL (2015)
Commentary: Making middle income countries pay full price for drugs is a big mistake
Priti Radhakrishnan
BMJ-BRITISH MEDICAL JOURNAL (2015)
Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries
Tuan Anh Nguyen et al.
HEALTH POLICY AND PLANNING (2015)
Market-access agreements for anti-cancer drugs
Katelijne van de Vooren et al.
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE (2015)
Policies and Programs to Facilitate Access to Targeted Cancer Therapies in Thailand
Rosarin Sruamsiri et al.
PLOS ONE (2015)
Redefining global health priorities: Improving cancer care in developing settings
Asad Moten et al.
JOURNAL OF GLOBAL HEALTH (2014)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille Abboud et al.
BLOOD (2013)
Higher US Branded Drug Prices And Spending Compared To Other Countries May Stem Partly From Quick Uptake Of New Drugs
Panos Kanavos et al.
HEALTH AFFAIRS (2013)
Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries
Alexandra Cameron et al.
EPILEPSIA (2012)
Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries
Alexandra Cameron et al.
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2011)
High medicine prices and poor affordability
Guk-Hee Suh
CURRENT OPINION IN PSYCHIATRY (2011)
Delivering affordable cancer care in high-income countries
Richard Sullivan et al.
LANCET ONCOLOGY (2011)
Expansion of cancer care and control in countries of low and middle income: a call to action
Paul Farmer et al.
LANCET (2010)
The Impact of Pharmaceutical Cost Containment Policies on the Range of Medicines Available and Subsidized in Finland and New Zealand
Katri Aaltonen et al.
VALUE IN HEALTH (2010)
The PAHO Strategic Fund: a mechanism to facilitate access to medicines
Myrza M. L. de L. Horst et al.
REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH (2010)
International price comparisons of Alzheimer's drugs: a way to close the affordability gap
Guk-Hee Suh et al.
INTERNATIONAL PSYCHOGERIATRICS (2009)
How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
Tito Fojo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
International prices and availability of pharmaceuticals in 2005
Patricia M. Danzon et al.
HEALTH AFFAIRS (2008)
The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries
Shanthi Mendis et al.
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2007)
Cost of cancer care: Issues and implications
Neal J. Meropol et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
European health systems and cancer care
A. Micheli et al.
ANNALS OF ONCOLOGY (2003)
分享论文
